sevenspikes.themes.common.filters
sevenspikes.themes.common.closemenu

Losmapimod,≥99% (HPLC)

别名:6-[5-(Cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)nicotinamide

CAS:585543-15-3;分子式:C22H26FN3O2;分子量:383.46
制造商品牌: BSZH 科学公司
货号(SKU): L06152
CAS号: 585543-15-3
增值税发票 √ 免费送货 √ 订货电话:010-68689484
$185.13

产品描述

可溶于DMSO(76mg/mL)。

General description

一种有效的选择性的可口服的 p38 丝裂原活化蛋白激酶(MAPK)抑制剂。

Losmapimod is a drug developed by GlaxoSmithKline which acts as a selective inhibitor of the enzyme family known as p38 mitogen-activated protein kinases. p38 mitogen-activated protein kinases are mediators of inflammation. A Phase II human clinical trial for the treatment of COPD (chronic obstructive pulmonary disease) is underway. Inhibiting these enzymes has been shown to produce antidepressant and antipsychotic effects in animal studies, with the mechanism thought to involve increased neurogenesis probably related to BDNF release. Losmapimod has completed Phase II human clinical trials for the treatment of depression although its safety and efficacy have yet to be proven in further trials. Losmapimod is also being studied for cardiovascular disease. A Phase II trial to study its effects in myocardial infarction (heart attack) is ongoing。

Losmapimod是由葛兰素史克(GlaxoSmithKline)开发的药物,它是称为p38促分裂原活化蛋白激酶的酶家族的选择性抑制剂。 p38丝裂原激活的蛋白激酶是炎症的介质。 目前正在进行一项用于治疗COPD(慢性阻塞性肺疾病)的II期人类临床试验。 在动物研究中,抑制这些酶已显示出产生抗抑郁和抗精神病的作用,其机理被认为可能与BDNF释放有关,涉及神经发生的增加。 Losmapimod已完成用于治疗抑郁症的II期人类临床试验,尽管其安全性和有效性尚未在进一步的试验中得到证实。 Losmapimod也正在研究心血管疾病。 目前正在进行一项II期临床试验,以研究其对心肌梗塞(心脏病发作)的影响。

性质

Iupac Name6-{5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-N-neopentylnicotinamide
Inchi Code1S/C22H26FN3O2/c1-13-17(9-15(10-18(13)23)21(28)26-16-6-7-16)19-8-5-14(11-24-19)20(27)25-12-22(2,3)4/h5,8-11,16H,6-7,12H2,1-4H3,(H,25,27)(H,26,28)
Inchi KeyKKYABQBFGDZVNQ-UHFFFAOYSA-N


安全信息

风险声明 (欧洲) 23/24/25
安全声明 (欧洲) 26-36
WGK德国 WGK 3
商品规格
属性名称属性值
储存温度 Storage temp.-20°C低温冷冻
全球实时库存 Availability √美国St. Louis ≥ 55 | 欧洲Eur. ≥ 16 | 東京Tokyo ≥ 8 | 香港与北京 ≥ 10